Back
Speaker illustration

Ms Dongqing Chen

University of Newcastle, Newcastle (Australia)

Member of:

European Society of Cardiology

Presentations

The clinically active PARP inhibitor olaparib ameliorates doxorubicin-induced cardiotoxicity in both in vitro and in vivo model

Event: ESC Congress 2023

Topic: Drugs, Drug Targets

Session: Molecular cardio-oncology

Access
Like
Thumbnail

Doxorubicin-induced upregulation of follistatin-like 3 (FSTL3): a new therapeutic target

Event: ESC Congress 2022

Topic: Drugs, Drug Targets

Session: Acquired forms of heart failure: cancer and inflammatory disorders

Access
Like
Thumbnail

Follistatin-like 3 (FSTL3) levels are increased in acute heart failure patients

Event: ESC Congress 2021 - The Digital Experience

Topic: Biomarkers

Session: Acute heart failure e-posters

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources